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ABSTRACT
The purpose of this dissertation was to identify the effect of creatine (Cr)
supplementation during immobilization on muscle performance. Twenty-five
healthy, active male (n = 14; age 28 ± 5 years) and female (n = 11; age 22 ± 4
years) subjects performed wrist flexion exercise before (PRE) and after (POST)
one week of wrist/forearm cast immobilization. During the immobilization period,
subjects consumed Cr (20g) or placebo PL (4% CHO flavored solution)
interspersed throughout the day. On the first day of immobilization subjects
consumed two doses of Cr (10 g) or PL. Subjects consumed 5 g of Cr or PL on
four occasions from day 2 to day 7 for a total of 20 g·d-1. On day 8, subjects were
instructed to consume a total of 5 g CR or PL, and the cast was removed prior to
POST test. Exercise was performed on a custom developed rotational ergometer
device attached by a cord to suspended weights across a wall pulley. Wrist flexion
exercise commenced with an incremental protocol to fatigue followed by a 4.8 min
rest. Then constant-load exercise (CL1) was performed with the peak weight
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achieved in the incremental protocol for 2.4 min, followed by another 4.8 min rest.
The second constant-load exercise bout (CL2) used the same weight as CL1 for a
final 2.4 min endurance exercise bout. Total work and average power was
quantified by the kg load, the distance the weight was lifted, and the time to
conduct the work. Immobilization caused a significant decrement in forearm total
work (-3.17 ± 2.27% PL; -2.61 ± 1.89% CR) and average power (-3.43 ± 2.35%
PL; -2.61 ± 1.89% CR) during the incremental protocol, regardless of Cr
supplementation. During the first CL bout, both total work and average power
decreased in PL after immobilization (-28.9 ± 9.63%; p < 0.05), but not in CR.
However, during CL2, both total work and average power decreased in CR (work 14.39 ± 4.54%; power -10.52 ± 4.6% and PL (work -21.98 ± 8.28%; power -21.3 ±
8.25%) groups after immobilization. The significance of these findings are; 1) 7
days of wrist immobilization will significantly decrease wrist flexion work and
power, 2) this decrement can be slowed with Cr supplementation for an initial
constant load exercise bout performance, and 3) however, this beneficial effect
may be lost with repeated bouts of constant load exercise. Future research should
help elucidate the underlying mechanisms of fatigue after immobilization to
explain possible differences in incremental and constant load endurance exercise
performance.
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CHAPTER 1
Introduction
Creatine (Cr), which comes from the Greek word kreas, meaning flesh, is a
naturally occurring protein compound found in meat and fish. It is also endogenously
synthesized from the amino acids arginine, glycine, and methionine in the human liver
and pancreas (Wyss & Kaddurah-Daouk, 2000). In an average 70 kg adult, the total Cr
pool amounts to ∼120 g, of which most (∼ 95%) is contained in skeletal muscle with ∼
65% in phosphorylated form of phosphocreatine (PCr) (Casey & Greenhaff, 2000).
During high-intensity exercise, PCr hydrolysis plays a crucial role in skeletal muscle
metabolism by maintaining a high rate of adenosine triphosphate (ATP) production. Cr
acts through several mechanisms, including: 1) aids in rapid rephosphorylation of
adenosine diphosphate (ADP) back to ATP via the creatine kinase reaction (Hespel et al.,
2001; Yquel, Arsac, Thiaudiere, Canioni, & Manier, 2002); 2) enhances myosin head
cross-bridge recycling and tension maintenance (Wyss & Kaddurah-Daouk, 2000); 3)
buffers acidosis by consuming H+ during the creatine kinase reaction, thereby improving
cellular homeostasis (Mesa, Ruiz, Gonzalez-Gross, Sainz, & Garzon, 2002); 4) increases
the rate of glycolysis through the phosphofructokinase reaction and thus the rapid
production of ATP (Demant & Rhodes, 1999); 5) enhances oxidative phosphoylation and
decreases protein and/or nucleotide degradation via increased oxygen uptake coupled to a
reduction in ammonia accumulation (Rico-Sanz & Mendez Marco, 2002); and, 6)
shortens muscle relaxation time during intermittent maximal isometric contractions by
means of facilitated calcium uptake by the sarcoplasmic reticulum (Van-Leemputte,
Vandenberghe, & Hespel, 1999).
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Oral Cr supplementation at a dose of 20 g·day-1 for 3-5 days (loading phase)
increases total muscle creatine (TCr) content, free creatine (fCr), and PCr (Casey,
Constantin-Teodosiu, Howell, Hultman, & Greenhaff, 1996). Early work using muscle
biopsy showed that Cr ingestion favorably improved muscle metabolism by increasing
PCr availability in type II muscle fibers (Greenhaff, Bodin, Soderlund, & Hultman,
1994). Cr ingestion was also shown to enhance muscle PCr resynthesis during recovery
from intense muscle contractions resulting in enhanced fatigue resistance during short
duration high-intensity exercise (Balsom, Soderlund, Sjodin, & Ekblom, 1995).
Subsequent non-invasive research on human skeletal muscle in vivo using phosphorus
magnetic resonance spectroscopy (31 P MRS) has shown similar muscle metabolic
improvements during intermittent maximal exercise. Yiquel et al. (2002) examined the
effect of Cr ingestion (20g/day for 6 days) on muscle power, PCr resynthesis, inorganic
phosphate (Pi), and pH during 8 repeated brief bouts of maximal dynamic plantar flexion
exercise. Following Cr supplementation, resting muscle PCr increased by 15%, along
with an increased rate of muscle PCr resynthesis during recovery, a lower Pi
concentration, higher muscle pH, and improved maintenance of muscle power output. In
another study using 31P MRS by Rico-Sanz (2000), Cr supplementation (5 g∙d-1 x 11d)
reduced net muscle PCr utilization, Pi accumulation, and acidosis during repeated bouts
of low-intensity isometric exercise (32% of MVC) of the plantar flexors to exhaustion.
There is evidence that suggests Cr supplementation at rest and during resistance
training may be an effective intervention to reverse or maintain lower-body muscle mass
during and after limb immobilization (Hespel et al., 2001). Most recently, Johnston and
co-workers (2009) examined the effects of cast-induced immobilization of the upper limb
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between Cr and placebo interventions. After baseline measures of lean tissue mass (dualenergy X-ray absorptiometry), strength (1-repetition maximum [RM] isometric single
arm elbow flexion/extension), and muscle endurance (maximum number of single-arm
isokinetic elbow flexion/extension repetitions at 60% 1 RM), subjects had their dominant
or non-dominant upper limb immobilized at 90˚ elbow flexion for 7 days. Compared to
placebo, Cr supplementation better maintained muscle mass, elbow flexor strength,
elbow flexor endurance, elbow extensor strength, and elbow extensor endurance during
immobilization. These results indicate that short-term Cr supplementation attenuates the
loss in muscle mass and strength during upper-arm immobilization.
Limb immobilization, bed rest, weightlessness, and aging are all associated with a
decline in muscle strength and endurance capacity with concomitant reductions in muscle
size, type II muscle fiber diameter, mitochondrial enzyme activity, and high-energy
phosphate metabolism. There is evidence to suggest that reduced levels of resting muscle
PCr in the elderly may be responsible for the age-related decline in muscle strength and
endurance (McCully et al., 1991). In addition, PCr resynthesis rates following exercise
decrease by ∼8% every decade after 30 yr of age (McCully & Posner, 1992). Smith et al.
(1998) studied young (30 ± 5 yr) and middle-aged (58 ± 4 yr) men and women using 31P
MRS during single-leg knee-extension exercise. Resting muscle PCr was lower and
initial PCr resynthesis rate was slower in the middle-aged group. Following 5 days of Cr
ingestion at 0.3 g·kg-1·day, resting PCr increased 15% in the young group and 30% in the
middle aged group. The middle-aged group also had greater improvements in PCr
hydrolysis during exercise and initial PCr resynthesis rate after exercise compared with
the young group. These results suggest that Cr would be an effective nutritional
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supplement for improving muscle metabolism and performance for men and women of
increasing age, as well as if forced to endure prolonged inactivity (e.g. spaceflight) or
joint/limb immobilization such as during recovery from musculoskeletal injury.

Problem Statement
Cr supplementation has been shown to improve muscular strength and endurance
in a variety of studies and from a diverse number of research laboratories. However,
application of Cr supplementation to mitigate the atrophy and detraining from limb
immobilization in human subjects has only been researched by one prior investigation
(Johnston, Burke, MacNeil, & Candow, 2009). Though the results of Johnston et al.
(2009) were positive to the benefits of Cr supplementation to preservation of muscle
mass and strength following 7 days of upper-limb immobilization, this study did not
directly assess muscle work and peak power during forearm immobilization. Given that
there seems to be a role for Cr in maintenance of muscle integrity and function during
immobilization, which has application to athletes who are injured or the elderly, this topic
warrants further investigation to assess muscle function during and following high
intensity exercise. We expect that Cr supplementation will mitigate the decrement in
forearm work and power during one week of writs/forearm immobilization.

Purpose of the Study
This study was conducted to compare the effects of short term immobilization of
the forearm between Cr and placebo interventions. Forearm wrist flexion exercise during
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incremental exercise, and repeated bouts of intense exercise were analyzed for total
muscle work and average muscle power.

Hypotheses
The following research hypotheses were tested in this study.
Hypothesis I.
There will be a significant (p < 0.05) decrease in the PL group, but not the Cr group
following immobilization for work and power during an incremental, dynamic wrist
flexion exercise to exhaustion.
Rationale. Cr supplementation has demonstrated effectiveness to improve exercise
performance. Cr has also shown to attenuate muscle atrophy, strength, and endurance of
the upper limbs following cast-induced immobilization (Johnston, Burke, MacNeil, &
Candow, 2009).
Hypothesis II.
There will be a significant (p < 0.05) decrease in the PL group, but not the Cr group
following immobilization for work and power during constant load dynamic wrist flexion
exercise 4.8 minutes following the incremental exercise bout to exhaustion.
Rationale. While the results from the Johnston et al. (2009) study measured isometric
strength and endurance, it is reasonable to expect Cr supplementation will maintain
dynamic wrist flexion exercise to fatigue following immobilization.
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Hypothesis III.
There will be a significant (p < 0.05) decrease in the PL group, but not the Cr group
following immobilization for work and power during constant load dynamic wrist flexion
exercise 4.8 minutes following the first steady-state exercise bout to exhaustion.
Rationale. Cr supplementation has been demonstrated to improve intermittent exercise
performance through several physiologic mechanisms, most notably rephosphorylation of
ATP via the creatine kinase reaction. Therefore, it is reasonable to expect Cr will improve
forearm flexion work and power during the final steady-state exercise bout.

Scope of the Study
Twenty-five healthy, resistance-trained male (n = 14) and female (n = 11)
subjects were randomly assigned to either a treatment group or placebo group.
Approximately one week prior to forearm immobilization, both groups performed a
familiarization protocol consisting of incremental wrist flexion exercise to exhaustion
determine the peak load for the incremental protocol. Immediately after the incremental
protocol, subjects rested for 4.8 min, and then perform two additional bouts of wrist
flexion exercise involving 2.4 min of exercise with a load equal to the load attained
during the last stage of the incremental protocol, interspersed with 4.8 min of recovery.
Subjects completed pre-testing on day 1, and then ingested Cr or placebo starting with the
evening meal on day 1. On day 2, subjects were fitted with a hand/forearm cast, and the
cast remained on through the morning of day 8. The cast was then removed immediately
prior to post-immobilization exercise testing.
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Assumptions
The following assumptions were made in this study:
1. The subjects ingested Cr as instructed.
2. All subjects had not used Cr supplements for at least 2 months prior to testing.
3. The subjects remained in a cast during the treatment period.
4. The subjects exerted maximal effort for the exercise test protocol.

Limitations
The following limitations were identified for this study:
1. The study group consisted of healthy, trained male and female subjects in the age
range of 18 to 33 years old; therefore, the results can only be generalized to a
healthy, trained population of similar age.
2. This study measured the muscles of the forearm. Caution must be employed when
generalizing the findings to muscles or muscle groups that may contain different
fiber types and/or metabolic properties.
3. This study used immobilization to study the effects of muscle atrophy. Care
should be used when extrapolating the results to other conditions that exacerbate
muscle atrophy such as aging, muscle wasting diseases, spaceflight, or bed rest.
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Significance of the Study
This study identified the effectiveness of Cr supplementation to maintain muscle
function during short-term immobilization. No prior study has used forearm/wrist
immobilization combined with Cr supplementation. Additionally, muscle power output
and time to fatigue were assessed. The results of this study may provide insight into the
muscle performance changes that occur during immobilization as well as the
effectiveness Cr supplementation to offset muscle dysfunction. If demonstrated effective,
Cr supplementation would be a cost-effective therapeutic intervention to slow the
changes in muscle during immobilization. Future research could explore the effectiveness
of Cr supplementation during other muscle disuse scenarios such as bed rest and
spaceflight.
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Definition of Terms
The terms in this study have been operationally defined as follows:
Acidosis. A decrease in pH (increase in free hydrogen ion concentration).
Adenosine diphosphate (ADP). A nucleotide that is the product of the ATPase reaction.
Adenosine triphosphate (ATP). A multifunctional nucleotide that transfers chemical
energy within cells for metabolism.
Amino acids. Molecules that contain a carboxylic acid group, an amine group, and a
variety of side chains.
Ammonia. A bi-product of the AMP deaminase reaction that forms IMP.
Anabolism. The metabolic process that requires energy to build molecules from smaller
units.
Anaerobic capacity. The capacity of skeletal muscle to regenerate ATP from nonmitochondrial respiration pathways.
Anaerobic metabolism. Reactions of metabolism that do not require the presence of
oxygen.
Anaerobic threshold. The exercise intensity when there is an abrupt increase in creatine
phosphate hydrolysis and glycolysis, resulting in increased lactate production and the
decrease in muscle creatine phosphate.
Atrophy. Decrease in size.
Buffering capacity. The capacity to remove free hydrogen ions from solution.
Catabolism. The metabolic process involving the breakdown of relatively complex
molecules with the subsequent release of energy.
Concentric muscle action. Muscle actions involving muscle shortening.
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Creatine. A nitrogenous compound that is a product of the creatine kinase reaction.
Creatine kinase. An enzyme that facilitates the regeneration of ATP via creatine
phosphate hydrolysis and ADP.
Creatine monohydrate. The supplemental, powdered form of creatine widely used a
dietary supplement.
Creatine phosphate. See phosphocreatine.
Dietary supplement. Substances that are not considered drugs or normal foods or food
additives.
Eccentric muscle action. Muscle actions involving muscle lengthening.
Endogenous. Substances that are produced within an organism or cell.
Ergogenic. That which improves physiologic variables associated with exercise
performance such as drugs or dietary supplements.
Ergometry. A science concerning the measurement of work.
Exogenous. Substances that are produced outside an organism or cell.
Extracellular. Outside the cell.
Free creatine. Creatine in the skeletal muscle cells that is in the non-phosphorylated form.
Hypertrophy. Increase in size.
Inorganic phosphate. Phosphorus found as a free phosphate ion in solution.
Intracellular. Inside the cell.
Muscle disuse. General term used to describe situations and consequences of reduced
muscle actions such as during immobilization, bed rest, or spaceflight.
Palmaris longus. An anterior arm muscle that acts as a wrist flexor. It originates on the
medial epicondyle of the humerus and inserts on the palmar surface of the hand.
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Phosphagen system. Energy system used to generate ATP quickly during high-intensity
exercise through the ATPase reaction, creatine kinase reaction, adenylate kinase reaction,
and AMP deaminase reaction.
Phosphocreatine. Creatine in the phosphorylated form that serves as an energy store in
skeletal muscle.
Phosphorus Magnetic Resonance Spectroscopy (P-MRS). A non-invasive method of
measuring muscle biochemistry with a magnetic field that excites phosphorus nuclei to
produce a detectable signal used to quantify high energy phosphate metabolites.
Plasma Volume. The non-cellular portion of the blood.
Power. Work performed in a given time period.
Protein. Compounds consisting of one or more polypeptides, or peptide-bound chains of
amino acids.
Total Body Water. The total amount of water in the body.
Work. Force applied against gravity for a given distance.
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CHAPTER 2
This chapter presents a review manuscript, entitled “Exploring the Potential of
Creatine to Maintain Muscle Function During Immobilization” that will be submitted to
the International Journal of Sports Nutrition and Exercise Metabolism. It is authored by
Jeremy C. Fransen and Suzanne Schneider. The manuscript follows the formatting and
style guidelines of the journal. The references cited are provided at the end of the
manuscript.
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ABSTRACT
Limb immobilization (casting) results in a loss of muscle mass along with decrements in
muscle strength and endurance. In addition, immobilization has been shown to impair
high energy phosphate catabolism in skeletal muscle. Creatine ingestion in conjunction
with resistance training can significantly increase muscle force production, augment
muscle size increases, and improve energy-rich phosphate catabolism in skeletal muscle.
Surprisingly, there are few research studies investigating the potential of oral creatine
supplementation to mitigate the muscle changes during immobilization. Early
investigations found that creatine supplementation can maintain muscle size, strength,
and endurance during short-term (1-2 wk) immobilization. Future research should focus
on whether creatine supplementation can also prevent muscle metabolic consequences
during immobilization. Creatine ingestion during short-term immobilization may help to
identify the underlying mechanisms that contribute to the reported ergogenic effects.

Key Words: Casting, Muscle performance, Creatine phosphate
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INTRODUCTION
The effects of muscle disuse include decreases in muscle cross-sectional area
(CSA) (Hather, Adams, Tesch, & Dudley, 1992), reduced muscle specific force (Yue,
Bilodeau, Hardy, & Enoka, 1997), alterations in muscle contractile properties (Seki,
Taniguchi, & Narusawa, 2001), increased muscle protein degradation (Berg, Dudley,
Haggmark, Ohlsen, & Tesch, 1991), change in muscle fiber type distribution from type I
to type IIb fibers (Desplanches, Mayet, Sempore, & Flandrois, 1987), neuromuscular
adjustments (Duchateau & Hainaut, 1987), and a shift in muscle metabolic properties
including loss of oxidative properties (Neeti Pathare et al., 2005). The aforementioned
muscle changes occur as a result of inactivity, ageing, bed rest, spaceflight, limb
suspension, or joint immobilization. Joint immobilization has been particularly useful as
a model to investigate changes in skeletal muscle from disuse (Berg et al., 1991; Miles et
al., 1994). Recent evidence suggests that creatine (Cr) supplementation may slow the rate
of muscle loss and dysfunction during cast-induced immobilization (Johnston, Burke,
MacNeil, & Candow, 2009). The goal of this article is to review the role of Cr in muscle
energy metabolism and exercise performance, muscle function, the consequences of
muscle disuse during immobilization, and to argue for the potential use of oral Cr
supplementation to minimize the changes in muscle size and function during
immobilization.

Biochemistry of creatine
Cr is a nitrogenous amino acid compound with the chemical name αmethylguanidinoacetic acid. Cr has a positive charge with a molecular weight of 131 Da
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(Mesa, Ruiz, Gonzalez-Gross, Sainz, & Garzon, 2002). Cr was discovered in 1835 by the
French scientist Chevreul, with the first supplementation studies beginning in the early
1900s (Cathcart, 1909; Chanutin, 1926; Mendel & Rose, 1911). The role of Cr in energy
metabolism was clarified with the discovery of phosphocreatine (PCr) in 1927, followed
by the creatine kinase (CK) reaction in 1934 (Wyss & Kaddurah-Daouk, 2000). CK
catalyzes the reversible transfer of the γ-phosphate group of ATP to the guanidine group
of Cr to yield ADP, PCr and H+ (Fig. 1). Thus, Cr is the substrate of CK to form PCr
(Mesa et al., 2002). The high-energy phosphoryl group of PCr is transferred to ADP
during exercise to maintain ATP concentrations in the muscle. Cr can then be recycled or
transformed to creatinine (Crn) to be excreted in the urine (Mesa et al., 2002). During
recovery from intense exercise, the large pool of PCr in fast-twitch skeletal muscle allows
immediate regeneration of ATP (Fig. 1). Due to the high cytosolic content of CK in
skeletal muscle, the CK reaction remains at near equilibrium maintaining an almost
constant ATP concentration, and thus buffers the cytosolic phosphorylation potential that
is crucial for optimal cellular ATPase function (Wyss & Kaddurah-Daouk, 2000).
The demand for Cr approximates 2 g·d-1 to replace the catabolized Cr that is
excreted from the kidneys as Crn (Harris, 1992). The daily requirement for Cr can be met
through a combination of de novo biosynthesis (~ 1 g·d-1) and intestinal absorption of
dietary Cr (~ 1 g·d-1) (Mesa et al., 2002). The amino acids glycine, arginine, and
methionine are involved in the endogenous synthesis of Cr in the liver, kidney, and
pancreas. The first two steps of Cr biosynthesis involve the transfer of the amidino group
of arginine to glycine, which is catalyzed by L-arginine:glycine amidinotransferase
(AGAT), to yield L-ornithine and guanidinoacetate. Guanidinoacetate is then methylated
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at the amidino group via the action of S-adenosyl-L-methionine:N-guanidinoacetate
methyltrasferase (GAMT) to yield S-adenosyl-L-homocysteine and Cr (Wyss &
Kaddurah-Daouk, 2000). The formation of guanidinoacetate by AGAT is the ratelimiting step in Cr synthesis (Walker, 1979). Endogenous Cr biosynthesis is reduced
following increased dietary Cr ingestion (Walker, 1979), but returns to normal once
dietary intake is reduced (Persky & Brazeau, 2001).
An omnivorous diet provides approximately 1 g·d-1 of Cr with normal plasma Cr
levels ranging from 50-100 μmol·L-1 (Harris, 1992; Williams, 1998). Typical dietary
sources of Cr include meat, fish, and other animal products. Following ingestion, Cr is
absorbed by the gut and enters the bloodstream where it accumulates in CK-containing
tissues, predominately skeletal muscle. Greater than 90% of Cr enters the skeletal muscle
through the binding of specific transporter proteins located in the muscle fiber
membranes (Mesa et al., 2002). The main Cr transporter expressed in skeletal muscle is
creatine transporter 1 (CRT-1) (Sora et al., 1994). CRT-1 belongs to a super-family of
neurotransmitter transporters and is mediated by Na+-K+ ATPase mechanisms which are
dependent on extracellular concentrations of Na+ and Cl– (Dai, Vinnakota, Qian, Kunze,
& Sarkar, 1999). The CRT-1 transport mechanism demonstrates a Michaelis-Menten
constant (Km) for Cr in the micromolar range of 15–30 μmol·L-1, which allows for
sufficient Cr transport into skeletal muscle (Sora et al., 1994).
An average 70 kg male maintains approximately 120 g of Cr, of which 95% is
stored in the skeletal muscle. The total creatine (TCr) pool in the muscle exists as both
free creatine (FCr) and PCr, with approximately 60% of the TCr as PCr, and the
remainder as FCr (Williams, 1998). As explained earlier, Cr is an important source of
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energy for muscle contraction because of its rapid phosphorylation to form PCr, along
with the reversible rephosphorylation of ADP to form ATP via the CK reaction. Due to
the limited availability of ATP and PCr in muscle, Cr supplementation may increase TCr
concentrations, facilitate intramuscular PCr and subsequent ATP formation, thus
prolonging high-intensity exercise performance (P. D. Balsom, Soderlund, K., Sjodin, B.,
& Ekblom, B., 1995). Cr supplementation has also been shown to enhance myosin head
cross-bridge recycling (Wyss & Kaddurah-Daouk, 2000), buffer acidosis by consuming
H+ during the CK reaction (Mesa et al., 2002), increase the rate of glycolysis through the
phosphofructokinase (PFK) reaction (Demant & Rhodes, 1999), and shorten muscle
relaxation time during intermittent maximal isometric contractions (Vandenberghe, Van
Hecke, Van Leemputte, Vanstapel, & Hespel, 1999).

Figure 1: The creatine kinase reaction
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Muscle changes during immobilization
There are substantial immediate and longer-term physiologic changes in human
skeletal muscle as a consequence of disuse. Muscle fiber atrophy is one of the most
studied responses to muscle disuse in humans (Sargeant, Davies, Edwards, Maunder, &
Young, 1977a). Early research on the effects of muscle atrophy was conducted on
patients that were plaster cast immobilized following limb trauma or surgery (Gibson et
al., 1987; Haggmark, Jansson, & Ericksson, 1981; Sargeant et al., 1977a; Young,
Hughes, Round, & Edwards, 1982). It should be noted that trauma, surgery, and pain may
accelerate the atrophic response in the immobilized limb (Wolfe, Jahoor, & Hartl, 1989).
Subsequent research has used immobilization as a model for muscle disuse atrophy in
healthy volunteers (Miles et al., 1994; Yasuda, Glover, Phillips, Isfort, & Tarnopolsky,
2005). Additional models of disuse atrophy include limb suspension (Dudley et al., 1992)
and bed rest (LeBlanc et al., 1988), which are often used to investigate muscle changes
incurred during spaceflight. Although it is tempting to assign a value to the rate of muscle
change or loss during disuse, research clearly shows that the type of disuse protocol and
the muscle group affected determines the rate of decrement in size and function of the
muscle (Brian C Clark, 2009).
Muscle atrophy following immobilization has been a topic of inquiry for over a
century. Clinical observations of human skeletal muscle atrophy following mobilization
corroborated earlier research with monkeys (Chor & Dolkart, 1936; Willis, Caiozzo,
Yasukawa, Prietto, & McMaster, 1982). Anthropometrically measured leg volume has
shown a 12% reduction following a mean of 131 days of leg immobilization (Sargeant,
Davies, Edwards, Maunder, & Young, 1977b). Compared to disuse models of bed rest
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and lower limb suspension, immobilization resulted in greater atrophy (20% decrement
versus 8%) of the quadriceps femoris muscle (Convertino, Doerr, Mathes, Stein, &
Buchanan, 1989). Veldhuizen et al. (1993) investigated the effect of thigh muscle size
and function following four weeks of knee immobilization. Quadriceps cross-sectional
area (CSA) was calculated with computed tomography (CT) and showed a decrease of
21% ± 7% (p < 0.05). In addition, muscle biopsy from the vastus lateralis revealed a 16%
decrease (p < 0.05) in fiber diameter. There is less data and equivocal results concerning
the atrophy of the upper limbs. For example, 21 days of wrist immobilization has resulted
in no significant atrophy of the forearm muscles (Kitahara et al., 2003), while 9 days of
wrist immobilization resulted in significant atrophy (4.1% decrease in CSA) of the
forearm muscles (Miles et al., 1994). Although there was no significant change in
forearm muscle size following 21 days of wrist immobilization, there was a significant
decrease in grip strength and endurance and a prolonged post-exercise PCr recovery
period.
There are also significant alterations in neuromuscular properties that appear
within the first few days of muscle disuse. Research suggests that neural factors,
primarily central activation, can explain approximately 50% of the strength loss during
four weeks of muscle unweighting (B.C. Clark, Manini, Bolanowski, & Ploutz-Snyder,
2006). Immobilization also has been shown to alter the functional properties of motor
units (Seki et al., 2001). For example, Clark et al. (2008) evaluated the neuromuscular
properties during and following 3 weeks of hand/forearm cast immobilization.
Immobilization was shown to impair central activation of skeletal muscle, corticospinal
excitability, and muscle contractile properties. These changes are surprisingly rapid and
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can significantly alter motorneural activity in as little as one week (Lundbye-Jensen &
Nielsen, 2008).
Deficits in strength following immobilization cannot entirely be accounted for by
decreases in muscle CSA and neural alterations. Metabolic factors, including changes in
inorganic phosphate (Pi), have been shown to contribute to altered muscle contractile
function (Cook & Pate, 1985). Pathare et al. (2005) studied the effects of 7 weeks of
immobilization of the ankle joint on skeletal muscle using 31P MRS and muscle biopsy.
Following immobilization, there was a significant decrease in plantar flexor torque and a
significant increase in the Pi concentration (p < 0.001). Single fiber measurements
demonstrated an inverse relationship between Pi concentration and relative force
production. The alterations in resting Pi concentration may contribute to strength deficits
during immobilization independent of decreases in CSA and neuromuscular impairments
(Pathare et al., 2006). These results suggest that Cr supplementation may be able to play a
role in maintaining muscle function during immobilization by maintaining a lower Pi/PCr
ratio and thus mitigating the decrease in muscle force production.

Creatine supplementation and skeletal muscle metabolism
Oral Cr supplementation at a dose of 20 g·d-1 for 3-5 days (loading phase)
increases total muscle creatine (TCr) content, free creatine (fCr), and PCr. Early work
using muscle biopsies showed that Cr ingestion favorably improved muscle metabolism
by increasing PCr availability in type II muscle fibers as well as enhancing muscle PCr
resynthesis during recovery from intense muscle contractions resulting in fatigue
resistance during short duration high-intensity exercise (Greenhaff, 1994; Balsom et al.,
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1995; Casey, Constantin-Teodosiu, Howell, Hultman, & Greenhaff, 1996). Subsequent
non-invasive research on human skeletal muscle in vivo using 31P MRS has shown
similar muscle metabolic improvements during intermittent maximal exercise.
Yquel et al. (2002) examined the effect of creatine ingestion at 20 g·d-1 for 6 days
on muscle power, PCr resynthesis, inorganic phosphate (Pi), and pH during 8 repeated
brief bouts of maximal dynamic plantar flexion exercise. 31P MRS of the medial
gastrocnemius muscle was recorded on a superconducting magnet operating at 4.7 Tesla.
Following Cr supplementation, resting muscle PCr increased by 15%, along with an
increased rate of muscle PCr resynthesis, a lower Pi concentration, higher muscle pH, and
improved maintenance of muscle power output. In another study using 31P MRS by RicoSanz (2000), Cr supplementation (5 g ·d-1 x 11days) reduced net muscle PCr utilization,
Pi accumulation, and decreases in pH during repeated bouts of low-intensity isometric
exercise (32% of MVC) of the plantar flexors to exhaustion. These results suggest that Cr
supplementation improves muscle metabolism during intermittent intense exercise due to
a combination of enhanced muscle PCr stores, lowered Pi, higher pH, and improved PCr
recovery kinetics.
The changes in muscle metabolism following Cr supplementation may be
influenced by age, the muscle or muscle groups being tested, the type of muscular
contraction, or the method used to assess PCr recovery kinetics. Smith et al. (1998)
compared the effects of Cr supplementation on young and middle-aged men and women
during dynamic knee-extension exercise in a whole body magnet resonance system and
concluded that Cr ingestion improved PCr availability and resynthesis rate in middleaged versus younger individuals. Other research have shown no effect of Cr
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supplementation on PCr resynthesis rate of the gastrocnemius muscle during intermittent
plantar flexor isometric contractions (Vandenberghe et al., 1999). Subsequent research
have even shown a slowing of the PCr kinetics during exercise and recovery following Cr
supplementation (Jones, Wilkerson, & Fulford, 2009). It should be noted, however, that
both of the aforementioned studies finding no improvement or impaired PCr recovery
kinetics reported an increase in resting PCr concentrations and subsequent improvements
in muscle performance following Cr supplementation. While the exact mechanisms of
muscle metabolic improvements may be debatable, the improvements in muscle strength
and endurance following Cr supplementation remain consistent throughout the literature.

Creatine supplementation and short-duration high intensity exercise
Cr supplementation (~ 20 g·d-1) can increase isokinetic peak muscle torque
(Greenhaff et al., 1994; Rossouw et al., 2000), peak power (Green et al., 2001), as well as
improve 1 RM strength performance (Chrusch et al., 2001). Cr supplementation has been
shown to increase muscle power during repeated, short bouts of high-intensity exercise in
young healthy females and men 30-60 years of age (Bemben & Lamont, 2005; Lemon,
2002). For example, Cr supplementation (5 × 6 g·d-1) maintained exercise power by
mitigating the decline in work output from baseline over 10 6-s bouts of intermittent
high-intensity cycling exercise (P. D. Balsom, Ekblom, B., Soderlund, K., Sjodin, B., &
Hultman, E., 1993). Cr supplementation (5 × 5 g·d-1) increased peak power by 20.1%
(from 1061 ± 124 to 1325 ± 69 Watts) and mean power by 14.4% (from 582 ± 58.6 to
699 ± 26.1 Watts) during three Anaerobic Wingate Tests (AWT) with six minutes of
active recovery between bouts (Havenetidis, 2003). Ziegenfuss et al. (2002) studied the
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effects of 3 days of Cr supplementation (0.35 g·kg-1 of fat-free mass) on 10 male and 10
female power athletes during six maximal 10 s cycle sprints interspersed with 60 s of
recovery. Cr supplementation resulted in statistically significant increases in body mass
(0.9 +/- 0.1 kg, p < 0.03), total work during the first sprint (p < 0.04), and peak power
during sprints 2 to 6 (p < 0.10).
The improvements in exercise performance from Cr supplementation may be due
to increased skeletal muscle PCr which may serve as a temporal energy buffer as well as
a modulator of glycolysis resulting in delayed neuromuscular fatigue. Stout et al. (2000)
found improvements in neuromuscular fatigue after 5 days of Cr loading (4 × 5 g·d-1) in
trained female athletes, with a significant (p < 0.05) increase in physical working
capacity at the fatigue threshold. Most recently, Smith et al. (2007) examined the effects
of 5 days of Cr loading (4 × 5 g·d-1) versus placebo (PL– 10 g of flavored dextrose
powder) on the electromyographic fatigue threshold (EMGFT) in college-aged women.
Prior to and following supplementation, each subject performed a discontinuous
incremental cycle ergometer test to determine their EMGFT value from the vastus lateralis
muscle. Cr supplementation increased EMGFT from pre- to post-supplementation by
14.5% ± 3.5% (p = 0.009). There was no change for the PL group (-2.2 ± 5.8%; p =
0.732). These results suggest that Cr may delay the onset of neuromuscular fatigue during
intermittent high intensity exercise.

Creatine supplementation and moderate to long-duration exercise
In addition to the improvements during high-intensity exercise, there is evidence
that Cr supplementation can improve moderate to long-duration exercise performance.
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Preen et al. (2001) examined the effect of Cr supplementation (20 g∙d-1 for 5 days) on
long-term (~80 min) repeated-sprint cycle exercise (10 sets of 5 or 6 x 6 s maximal bike
sprints). Total work done increased 6% (from 251.7 ± 18.4 kJ to 266.9 ± 19.3 kJ; p <
0.05) following Cr ingestion whereas there was no change in the placebo group (254.0 ±
10.4kJ to 252.3 ± 9.3 kJ; NS). Cr supplementation has been shown to improve VO2
kinetics during exercise below the ventilatory threshold (VT)] (Jones, Carter, Pringle, &
Campbell, 2002). Nelson and co-workers (2000) investigated the effects of 7 days of Cr
supplementation (4 × 5 g·d-1) on cardiorespiratory responses to a graded exercise cycle
test to exhaustion. Cr significantly increased (p < 0.05) total test time vs. placebo. In
addition, VO2 and heart rate were significantly lower at the end of each of the first five
exercise stages following Cr supplementation, but were unchanged after placebo.
Moreover, Cr supplementation increased the VT (pre Cr = 2.2 ± 0.4 l ∙ min-1 or 66% of
VO2peak vs. post Cr = 2.6 ± 0.5 l ∙ min-1 or 78% of VO2peak). In another study by RicoSanz and Mendez Marco (2000), Cr supplementation (20 g∙d-1 x 5d) improved time to
exhaustion during cycling from 29.9 ± 3.8 min pre-Cr to 36.5 ± 5.7 min post-Cr (p <
0.05) versus no change in the placebo group [38.1 ± 5.6 and 40.8 ± 5.7 min pre-treatment
and post-treatment, respectively (NS)].

Molecular mechanisms of creatine supplementation for muscle hypertrophy
More recently, research has focused on the effect of Cr supplementation on
molecular pathways in skeletal muscle synthesis and degradation. Olson et al. (2006)
investigated the influence of Cr and protein supplementation on satellite cell and
mononuclei number in human skeletal muscle during 16 weeks of resistance training.
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Using a double-blind design, 32 healthy male subjects were assigned to strength training
(3 days per week) with either Cr (6-24 g; n = 9), protein (20g; n = 8), or placebo (n = 8).
Muscle biopsies were obtained at week 0, 4, 8, and 16 of the resistance training program.
Significantly greater (p < 0.05) enhancements in the proportion of satellite cells were
observed in the Cr supplementation group at weeks 4 and week 8. Furthermore, Cr
supplementation resulted in an increase of 14-17% in muscle mean fiber area (MFA) as
well as an increased number of mononuclei per fiber at week 4, 8 and 16, versus the
strength training plus protein group that increased MFA by 8% in week 16 only. The
results from this study demonstrate that Cr supplementation in conjunction with
resistance training augments the training-induced increases in satellite cells and
mononuclei in human skeletal muscle, resulting in enhanced muscle fiber growth
Cr can change the intracellular osmotic pressure resulting in movement of water
into the cell, which can be a stimulus for protein synthesis or slowing protein breakdown
(Ziegenfuss et al., 2002; Keller et al., 2003). The accumulation of Cr in skeletal muscle
appears to stimulate transcriptional factors that regulate contractile protein synthesis,
possibly as a result of increased myosin heavy chain synthesis (Willoughby, 2001). The
increases in lean body mass following Cr supplementation could also be mediated via
anabolic signaling pathways involving increases in insulin-like growth factor I (IGF-1),
mRNA expression and eukaryotic initiation factor-4e binding protein-1 (4E-BPI)
(Deldicque, 2005). Cr supplementation has been shown to upregulate mRNA content of
genes and protein content of kinases involved in osmosensing and signal transduction,
cytoskeleton remodeling, protein and glycogen synthesis regulation, satellite cell
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proliferation and differentiation, and regulation of DNA replication and repair (Safdar,
Yardley, Snow, Melov, & Tarnopolsky, 2008).

Creatine supplementation and immobilization
Hespel et al. (2001) studied the effects of Cr supplementation on muscle volume,
function, and myogenic transcription factor expression during 2 weeks of leg
immobilization and rehabilitation in human subjects (n = 22; 13 males and 9 females).
Using a double-blind design, half the subjects consumed either Cr (20 g ·d-1 down to 5 g
·d-1; n = 11) or placebo (maltodextrin; n = 11) for a total of 12 weeks (2 weeks
immobilization, 10 weeks rehabilitation). Cross sectional area (CSA) of the quadriceps
muscle was assessed by NMR imaging. Muscle dynamic power and isometric force of the
knee-extensor muscles were assessed on an isokinetic dynamometer. In addition, muscle
biopsy samples from the vastus lateralis were taken to evaluate muscle myogenic
transcription factors. Measurements were taken before and after immobilization, and after
weeks 3 and 10 of rehabilitation training. During rehabilitation, dynamic power and CSA
recovered at a faster rate in the Cr supplementation group versus the placebo (p < 0.05).
Following rehabilitation, only the Cr group increased myogenic regulatory factor 4
(MRF4) protein expression (p < 0.05), which was found to be correlated with the change
in mean muscle fiber diameter (r = 0.73). These results suggest that Cr can enhance
muscle strength and hypertrophy during rehabilitation following disuse atrophy.
Research using the rat model has demonstrated the effectiveness of Cr to attenuate
muscle wasting during immobilization (Aoki, Lima, Miyabara, Gouveia, & Moriscot,
2004). Cr loading for 14 days (7 days prior to immobilization and together with
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immobilization) increased muscle Cr content in the lower leg muscles of the soleus by
25% and the gastrocnemius by 18%. This increase in intramuscular Cr content is
hypothesized to play a role in the mitigation of muscle loss induced by immobilization.
Additionally, the researchers found an additive effect on myosin heavy chain (MHC)
shift to the fast phenotype with the combination of Cr supplementation and
immobilization.
Cr supplementation has been used during arm immobilization to investigate its
effect to alter the changes in muscle mass, strength, and endurance (Johnston et al.,
2009). Using a single-blind, placebo-controlled, crossover design for 29 days, Cr was
supplemented (20 g· d-1) to Cr naïve men (n = 7; 18-25 years) during 7 days of upperlimb immobilization. During immobilization, compared to placebo, Cr supplementation
better maintained muscle lean tissue mass (Cr + 0.9% vs. PL ‒3.7%) of the upper arm as
measured with dual-energy X-ray absorptiometry (DEXA). In addition, Cr
supplementation significantly (p < 0.05) maintained elbow flexor strength (Cr ‒4.1% vs.
PL ‒21.5%) and endurance (Cr ‒9.6% vs. PL ‒43%), and elbow extensor strength (Cr
‒3.8% vs. PL ‒18%) and endurance (Cr ‒6.5% vs. PL ‒35%) over placebo. These results
show that short-term Cr supplementation can slow down the muscle atrophy and strength
and endurance losses during periods of immobilization.
There are other mechanisms by which Cr supplementation may attenuate muscle
dysfunction during periods of immobilization. For example, Cr supplementation has been
shown to improve glucoregulation in skeletal muscle (Ceddia & Sweeney, 2004).
Investigation into the effect of oral Cr supplementation on glucose transporter type 4
(GLUT4) protein content along with muscle glycogen and TCr content during
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immobilization and subsequent training was conducted (Eijnde, Urso, Richter, Greenhaff,
& Hespel, 2001). The right leg of each participant was immobilized for two weeks after
which all subjects participated in a resistance exercise program for 10 weeks.
Immobilization decreased GLUT4 in the placebo group by 20% (p < 0.05) with no
significant change in the Cr group (+ 9%, NS). During rehabilitation, Cr intake increased
GLUT4 by ~40% (P < 0.05), whereas the placebo group normalized pre-immobilization
levels. Moreover, muscle glycogen and TCr were higher with Cr supplementation
following 3 weeks of retraining. These results suggest that oral Cr ingestion may improve
glucoregulation during immobilization and during subsequent rehabilitation training.

Safety of creatine supplementation
In the scientific literature, Cr has been shown to be a safe and effective
supplement. In fact, weight gain is the only documented side effect of Cr ingestion
(Dalbo, Roberts, Stout, & Kerksick, 2008). Despite the impressive safety record,
concerns have been raised by the popular media and scientific community regarding
possible adverse effects of Cr supplementation. There have been anecdotal reports in the
popular literature that Cr may cause gastrointestinal upset, cause diarrhea, and promote
muscle cramping and dehydration (Terjung et al., 2000). Schilling et al. (2001) examined
the long-term (0.8 – 4 yr) safety of Cr supplementation in 26 competitive athletes (18
male and 8 females, 24.7 ± 9.2 yr) and found no evidence of increased incidence of
muscle injury, cramps, or any other side effects. Some researchers speculated that Cr
supplementation could result in an intracellular fluid shift that could reduce the
extracellular fluid compartment and impair thermoregulation. In a recent meta-analysis
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(Lopez et al., 2009), the authors concluded that there is no evidence that supports the
concept that Cr supplementation either hinders the body’s ability to dissipate heat or
negatively affects body fluid balance. Controlled experimental trials of athletes
exercising in the heat resulted in no adverse effects from Cr supplementation at
recommended dosages of 5-20 g·day-1.
There are claims that Cr supplementation may promote liver damage and increase
renal stress and/or impair renal function (Juhn, 1998). The concerns of Cr
supplementation on renal physiology can be traced to four case studies of possible renal
dysfunction in individuals believed to have been supplementing Cr (Kuehl et al., 1998;
Pritchard & Kalra, 1998; Koshy et al., 1999; Loud et al., 2001). Conclusions regarding
these case studies have been criticized because two of these individuals had pre-existing
kidney disease, one may have been misdiagnosed, and the other was apparently taking
only 25 mg of Cr per serving, which makes the connection of Cr ingestion to renal
dysfunction dubious. In each of these cases, elevations in serum creatinine (Crn) were
initially used to diagnose renal stress. However, Cr is naturally degraded to Crn with the
increased serum Crn levels most likely due to the initial Cr loading phase. Studies
measuring urinary Crn clearance and/or iohexol infusion techniques to assess glomular
filtration found no renal dysfunction in individuals ingesting Cr from 21 months to longer
than 5 years (Poortmans et al., 1997; Poortmans & Francaux, 1999; Rasmussen et al.,
1999; Robinson et al., 2000). In summary, there is no scientific evidence that Cr
supplementation at recommended doses in healthy individuals can induce impairment in
renal function (Mesa et al., 2002). Likewise, there is no scientific evidence to suggest that
Cr has any impact on liver function following short- or long-term supplementation
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(Bemben & Lamont, 2005). Robinson et al. (2000) reported no adverse effects on hepatic
function during short-duration (20 g ·d-1 for 5 days) or long-term (3 g ·d-1 for 63 days) Cr
supplementation.
In an effort to examine the long-term health effects of Cr supplementation,
Kreider et al. (2003) studied 98 college football players over a 21-month period. Cr was
administered at 15.75 g·d-1 for 5 days and then averaged 5 g·d-1 for the remainder of the
study. Fasting blood and 24-hr urine samples were collected at 0, 1, 1.5, 4, 6, 10, 12, 17,
and 21 months of training. Short or long-term Cr supplementation had no significant
effect on a 54-item panel of quantitative blood and urine markers or on a 15-item panel of
qualitative urine markers. Cr supplementation did not cause any clinically significant
changes in serum metabolic markers, muscle and liver enzyme efflux, serum electrolytes,
blood lipid profiles, red and white whole blood cell hematology, or quantitative and
qualitative urinary markers of renal function.
While the hypothetical side effects of Cr have been hotly debated in the public
media, less attention has been directed to several possible health benefits of Cr
supplementation. For example, research suggests that Cr may improve blood lipid
profiles. In a study conducted by Earnest et al. (1996), Cr supplementation (20 g·d-1 for 5
days, followed by 10 g·d-1 for 51 days) in mildly hypertriglyceridemic and
hypercholesterolemic subjects was shown to reduce plasma concentrations of total
cholesterol, triacylglycerols, and very-low-density lipoprotein-C by 5-26%, while having
no effect on low-density lipoprotein-C, high-density lipoprotein-C, and Crn
concentrations. There is also evidence that Cr supplementation may provide
neuroprotection against mitochondrial dysfunction by improving neuronal cell energy
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metabolism thus delaying apoptosis that occurs during neurodegenerative disorders such
as Alzheimer’s Disease (Brewer & Wallimann, 2000), Huntington’s Disease (Hersch et
al., 2006), and Parkinson’s Disease (Matthews, 1999).

Conclusions
Joint immobilization has multifaceted physiologic implications including changes
in musculoskeletal morphology, neuromuscular function, muscle contractile properties,
and metabolic processes. Cr supplementation in ambulatory subjects has been shown to
enhance muscle glycolytic metabolism and improve local muscle and total body exercise
performance. Moreover, Cr supplementation potentiates skeletal muscle anabolism when
combined with resistance exercise training, and when used alone, mitigates muscle
catabolism during periods of muscle disuse. Future research should focus on muscle
metabolic consequences of immobilization combined with Cr supplementation. Potential
benefits of Cr ingestion during short-term immobilization should be explored to identify
the underlying mechanisms that contribute to the reported protective effects. Longer
periods of immobilization and other disuse models such as bed rest and spaceflight could
then be investigated to determine if Cr provides similar protection. In conclusion, Cr
supplementation appears to be safe, effective, and possibly a useful countermeasure
against the deleterious effects of muscle changes during joint immobilization.
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CHAPTER 3
This chapter presents a complete manuscript that describes the study in traditional
journal article form including an abstract, introduction, experimental procedures, results,
conclusions, and reference section. The manuscript, entitled “Effect of Creatine
Supplementation on Wrist Flexion Exercise Performance after Immobilization” will be
submitted to the Journal of Strength and Conditioning Research. It is authored by Jeremy
C. Fransen, Robert Robergs, Micah Zuhl, and Suzanne Schneider. The manuscript
follows the formatting and style guidelines of the journal. The references cited are
provided at the end of the manuscript.
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ABSTRACT
The purpose of this study was to investigate the effect of creatine (CR) supplementation
during immobilization on skeletal muscle total work and average power during repeated
maximal intensity wrist dynamic contractions. Twenty-five healthy, active male (age 28
± 5 years) and female (age 22 ± 4 years) subjects performed wrist flexion exercise before
(PRE) and after (POST) one week of wrist/forearm cast immobilization. The wrist
flexion exercise consisted of an incremental protocol to fatigue followed by two constant
load (CL1 and CL2) exercise bouts at the maximal load obtained during the incremental
bout. During the immobilization period, in a double-blind study design, CR subjects (9
men and 4 women) consumed CR (20 g·day-1) while placebo (PL) subjects (5 men and 7
women) consumed a 4% carbohydrate solution. Immobilization caused a decrement in
forearm total work (-3.17% PL; -2.61% CR) and average power (-3.43% PL; -2.61% CR)
during the incremental protocol, regardless of CR supplementation. During the first CL
bout, both total work and average power decreased in PL after immobilization (-28.9 ±
9.6%; p < 0.05), but not in CR. However, during the second CL bout, both total work and
average power decreased in CR (work -14.39 ± 4.54%; power -10.52 ± 4.6% and PL
(work -21.98 ± 8.28; power -21.3 ±8.25%) groups after immobilization. Although the
peak power for wrist flexion did not decrease significantly after 1 week of
immobilization, arm endurance was significantly reduced. This impairment in arm
endurance can be prevented by the ingestion of CR, suggesting the loss in short term
endurance is due to either a depletion or altered kinetics of the phosphocreatine system.

Key Words: Casting, Creatine Phosphate, Muscle endurance
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Introduction
Numerous studies have documented the loss of muscle size and function after spaceflight,
bed rest, or joint immobilization (1, 3, 4). Immobilization has been used as a groundbased model to investigate the effects of microgravity on skeletal muscle function (4, 10,
14, 25). Muscle deconditioning occurs most rapidly during cast-induced immobilization,
followed by unloading with limb movement (i.e., unloaded limb models, bed rest, or
spaceflight) and, lastly, similar changes in muscle function occur with aging (6, 11, 20).
The loss of muscle function after disuse has been associated with a loss of muscle
contractile proteins (4), increased fatigability (36), neural adaptations (21), changes in
muscle fiber phenotype (32), impaired contractility (27), and a glycolytic shift in
metabolic properties (26).

Creatine monohydrate (CR) supplementation has been shown to potentiate increases in
muscle mass and strength when combined with resistance training in ambulatory subjects
(5, 34). CR supplementation also has been found to accelerate lower-body muscle mass
recovery following 2 weeks of knee flexor immobilization when combined with a
resistance training program (15). However, there is also evidence to suggest that CR
supplementation may slow the rate of muscle loss and dysfunction during
immobilization, independent of a resistance training stimulus. For example, CR
supplementation was found to mitigate muscle loss in rat planar flexors during 14 days of
hind limb suspension (1). In humans, Johnston et al. (17) reported CR supplementation
better maintained muscle mass, isometric strength, and dynamic endurance of the upper
arm flexors and extensors during isokinetic exercise after nine days of arm casting.
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However, there has been no research demonstrating the effectiveness of CR
supplementation on dynamic incremental wrist flexion exercise performance to fatigue
following immobilization. Moreover, research by Johnston et al. (17) did not perform
multiple endurance bouts, which may better reveal the ergogenic potential of CR as
research has shown improved performance during intermittent exercise bouts (36).

The purpose of this study was to investigate the effect of dietary CR supplementation to
preserve muscle endurance during repeated dynamic forearm flexion exercises following
immobilization. We hypothesized that dietary CR supplementation will maintain muscle
endurance after seven days of wrist casting, as evidenced by a maintenance of total work
and average power during repeated endurance bouts of high intensity, constant load wrist
flexion exercise.

Methods
Setting
All forearm ergometry data collection was conducted at New Mexico Resonance (NMR)
in Albuquerque, New Mexico. Casting of the forearm/hand was conducted at the Exercise
Physiology Laboratories at the University of New Mexico. Both of these facilities are
located at an altitude of 1600 m (5,400 ft) with an approximate barometric pressure of
630 mmHg.

Subjects
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Twenty-five active individuals (14 men, mean age 28 ± 5 years; 11 women, mean age 22
± 4 years) participated in this study. On their initial visit each subject gave informed
consent and completed a standard health history questionnaire to exclude subjects with
metal implants, a history of liver dysfunction, diabetes, neurological disorders, or renal
disease. The protocol was approved by the Institutional Review Board of the University
of New Mexico. Each participant performed aerobic and/or resistive exercise 3-6 d·wk-1.
They were asked to abstain from medications and were instructed to avoid changes in
their diet and refrain from physical activity for 24 hours immediately before the exercise
bouts in the study. Participants were excluded from the study if they had consumed
supplemental CR up to two months prior to the study.

Table 1: Group Characteristics
Group

Gender
M or F

Placebo
mean
std

5 M, 7 F

Creatine
mean
std

9 M, 4 F

Height
Cm

Weight
Kg

Age
yrs

171
13

65.8
13.4

23
3

173
9

76.5
22.2

25
4

Experimental Protocol
The twenty-five subjects were randomly assigned to either a treatment group (CR, n = 13;
9 men and 4 women) or placebo group (PL, n = 12, 5 men and 7 women). The CR and PL
groups were balanced in terms of age, height, and weight. This study was a double-blind
protocol, where neither the subjects nor the researchers were aware of the treatment (PL
or CR) during immobilization. Approximately one week before the immobilization of the
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non-dominant forearm/hand, each subject performed a familiarization protocol, which
consisted of a maximal incremental exercise test, followed by two constant load (CL1
and CL2) endurance tests. The maximal incremental test consisted of a continuous
incremental protocol with 0.8 min stages. The weight started at 1 kg or 2 kg and was
increased every 0.8 min by 0.5 kg or 1 kg, respectively depending on the baseline
strength of the subject. Forearm wrist flexion exercise continued until volitional
exhaustion (5.2 ± 0.69 min) using a custom-made arm ergometer (see below).
Immediately after the incremental exercise protocol, the subjects rested for 4.8 min, and
then performed two constant load wrist flexion exercise bouts of up to 2.4 min, against a
weight which equaled the maximal weight moved during the incremental protocol. These
two constant load endurance tests were separated by 4.8 min of recovery. The same
protocol (the incremental test and two endurance exercises) was repeated approximately
one week later before immobilization (pre-tests), and after 7 days of CR or PL ingestion
immediately after the cast was removed (post-tests).

Creatine Ingestion
Subjects were fitted with a forearm/wrist cast within one week of the familiarization test
(Figure 1). On the day of casting (day 1), each subject ingested either CR (5 g Cr + 10
grams sucrose) or placebo PL (10 g sucrose) starting with the afternoon meal and another
5 g of CR or PL with the evening meal, for a total of 10 g on day 1. The subjects were
instructed to ingest CR (20 g·d-1) or PL (10 g·d-1of a 4% CHO flavored solution)
throughout the rest of the immobilization period from days 2 to 7. The CR dose of 20 g·d1

is based on prior research demonstrating sufficient loading in the muscles after 5 days
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(13, 34, 35). They were instructed to consume 5 g of CR or the PL dissolved in 250 ml of
warm water on four occasions, at equally spaced intervals on day 2 to day 7. The subjects
were instructed to consume the supplement with food and to avoid simultaneous intake of
caffeine to ensure CR absorption. On day 8, the subjects were instructed to consume 5 g
CR or PL after breakfast. The cast was removed in the afternoon immediately prior to
repeating the exercise testing sequence.

Figure 1. Forearm cast

Ergometry
Dynamic exercise was performed using a custom-made forearm flexion ergometer, so
that the exercise could be performed with minimal movement and with the forearm
positioned within the coil of a 1.9 Tesla superconducting magnet. The pronated hand
rested around the rotational ergometer device, which was attached by a non-elastic cord
to weights which were raised and lowered across a wall pulley (Figure 2). Maximal
forearm wrist flexion exercise consisted of a downward wrist movement of 60° resulting
in a 10-cm vertical displacement of the weight. The subject then lowered the weight
under control back to the starting position. Repetitions were counted only if the subject
could perform a full range of motion as indicated by the sound of the ergometer clicking
and weight load hitting the end-point in the range of motion.
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During each exercise, the subjects sat with their non-dominant arm extended laterally
from their body, and with the forearm supported on the peripheral coil inside the magnet
(Figure 2). The subject was instructed to smoothly press down on the handle during the
concentric action (lifting the weight on the pulley) and to smoothly return the handle
during the eccentric component of the movement cycle. The subjects were instructed not
to strongly grip the handle during the contraction with the intent to isolate the wrist flexor
muscles while minimizing involvement of finger flexor muscles. All exercise was done at
a rate of one concentric and eccentric action cycle every 4 s and the rate was reinforced
by a clicking sound that corresponded to the concentric and eccentric actions. Concentric
and eccentric actions took 1.25 s each, with 1.5 s between contractions. During the
incremental protocol, the loads were increased in .5 kg or 1 kg increments, depending on
results during the familiarization session, until volitional fatigue, as indicated by the
inability to maintain repetition cadence and/or complete the full range of motion. The
subjects then rested for 4.8 min with their arm extended in the magnet. The subjects were
then asked to perform a 2.4 min bout of wrist flexion exercise with a load equal to the
load attained during the last stage of the incremental protocol. The subjects then rested
another 4.8 min with their arm in the magnet to collect recovery data. Following the rest
period, the subjects were again asked to perform one final 2.4 min exercise bout with the
same load as the previous 2.4 min stage. The two constant load exercise bouts were
terminated earlier if the subjects could not perform a complete exercise movement in the
prescribed time interval. The subject then rested for a final 20 min with their arm in the
magnet to obtain complete recovery data.
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Figure 2: Schematic of exercise apparatus
Calculations
Percent change (%Δ) in total work and average power were determined as follows:
%Δ = post-test – pre-test / pre-test x 100
Work (W) and Power (P) were determined as follows:
W (kg·m) = load (kg) x distance (0.1 m) x repetitions
W (Joules) = kg·m x 9.80665
P (kg·m·min−1) = W / Time (min)
P (Watts) = kg·m·min−1 / 6.118

Statistical Analysis
Independent t-tests confirmed there were no significant differences between the CR and
PL groups for anthropometric characteristics or for work or power exercise results before
immobilization.

Using data from before and after immobilization, the total work and average power
during the exercise bouts were analyzed using a 2-factor (group; creatine vs. placebo and
time; pre-cast, post-cast) ANOVA, with repeated measures on the time factor.
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For the graphical representations, non-paired t-tests were performed to compare the
percent changes in total work and average power between the pre- and postimmobilization tests. As CR was expected to have only positive effects on exercise
performance after immobilization, a one-tailed t-test was used to determine differences
between the group’s pre-and post-immobilization.

Except for anthropometric data and completed repetitions (± SD), all values are expressed
as mean ± SE. Statistical significance was set at p ≤ 0.05. Data were analyzed using
commercial statistical software (Statistica, v10, Statsoft Inc., Tulsa, OK). Sample size
estimates were computed using commercial software (GPower 3.1, University of Kiel,
Germany) and prior research which measured percent changes in isokinetic dynamic
endurance following a similar period of arm immobilization (17).

Results
Where data for both groups were combined (the ANOVA time effect), there were
significant (p < 0.05) decreases in forearm muscle work and average power after
immobilization during all three exercise bouts: the incremental protocol, CL1 and CL2.

Incremental ANOVA test results:
Incremental work decreased from 466.05 ± 12.98 J to 457.98 ± 47.29 J for CR and from
409.89 ± 51.93 J to 395.73 ± 50.82 J (Figure 3).
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Figure 3. Incremental work (J) before (Pre) and after (Post) immobilization for
creatine (CR) and placebo (PL) groups.

Incremental average power decreased from 6.21 ± 0.62 W to 6.11 ± 0.63 W for CR and
from 5.55 ± 0.69 W to 5.38 ± 0.68 W for PL (Figure 4). Table 2 quantifies the total
completed repetitions for CR and PL groups pre- and post-immobilization (± SD).

Table 2: Completed Repetitions for Incremental Protocol
Pre Immobilization

Post Immobilization

PL

78 ± 11

76 ± 12

CR

78 ± 11

77 ± 12
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Figure 4. Incremental power (W) before (Pre) and after (Post) immobilization for
creatine (CR) and placebo (PL) groups. Values are mean ± SE.

Incremental Percent Change Results:
From the non-paired t-tests of the percent changes, there were no significant differences
between groups in the percent change in total work (CR -2.61 ± 1.89% vs. PL -3.17 ±
2.27%; Figure 5) or average power (CR -2.61 ± 1.89% vs. PL -3.43 ± 2.35%; Figure 6)
during the incremental protocol pre- to post-immobilization. The peak load (kg) attained
during the incremental protocol was the same for all subject’s pre- and postimmobilization, with an average of 5.8 ± 2 kg (3.7 ± 0.5 kg for women and 7.3 ±1.2 kg
for men).

58

Figure 5. Percentage change in incremental work (J) after immobilization
from creatine and placebo. Values are mean ± SE.

Figure 6. Percentage change in incremental power (W) after immobilization
from creatine and placebo. Values are mean ± SE.
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CL1 ANOVA results:
Total work decreased in CL1 from 214.54 ± 70.18 J to 196.89 ± 61.17 J for CR and from
187.23 ± 71.2 J to 143.31 ± 92.47 J for PL (Figure 7). Power decreased in CL1 from 1.49
± 0.40 W to 1.32 ± 0.4 W for Cr and from 1.3 ± 0.49 W to 1.0 ± 0.64 W for PL (Figure
8). Table 3 quantifies the total completed repetitions for CR and PL groups pre- and postimmobilization (± SD).
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Figure 7. Constant load bout 1 work (J) before (Pre) and after (Post) immobilization
for creatine (CR) and placebo (PL) groups. Values are mean ± SE.
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Figure 8. Constant load bout 1 power (W) before (Pre) and after (Post) immobilization
for creatine (CR) and placebo (PL) groups. Values are mean ± SE.

Table 3: Completed Repetitions in CL1
Pre Immobilization

Post Immobilization

PL

36 ± 1

29 ± 10

CR

36 ± 0

33 ± 2

CL1 Percent Change Results:
Compared to placebo, creatine ingestion attenuated the decrease in wrist flexion total
work (CR -7.48 ± 1.62% vs. PL -28.96 ± 9.62%, p < 0.05; Figure 9) and power (CR 10.01 ± 2.38% vs. PL - 28.9 ±9.63%, p < 0.05; Figure 10).
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*

Figure 9. Percentage change in constant load bout 1 work (J) after immobilization
from creatine and placebo. Values are mean ± SE. *Significant group time
interaction, with creatine better maintaining strength over placebo (p < 0.05).

*

Figure 10. Percentage change in constant load bout 1 power (W) after immobilization
from creatine and placebo. Values are mean ± SE. *Significant group time
interaction, with creatine better maintaining strength over placebo (p < 0.05).
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CL2 ANOVA Results:
Total work decreased in CL2 from 214.09 ± 19.61 J to 188.21 ± 18.58 J for CR and from
185.80 ± 20.72 J to 155.32 ± 22.62 J in PL (Figure 11). Power decreased in CL2 from
1.49 ± 0.14 W to 1.25 ± 0.12 W in CR and from 1.29 ± 0.14 W to 1.07 ± 0.16 W in PL
(Figure 12). Table 4 quantifies the total completed repetitions for CR and PL groups preand post-immobilization (± SD).
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Figure 11. Constant load bout 2 work (J) before (Pre) and after (Post) immobilization
for creatine (CR) and placebo (PL) groups. Values are mean ± SE.
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Figure 12. Constant load bout 2 power (W) before (Pre) and after (Post) immobilization
for creatine (CR) and placebo (PL) groups. Values are mean ± SE.

Table 4: Completed Repetitions in CL2
Pre Immobilization

Post Immobilization

PL

36 ± 2

30 ± 10

CR

36 ± 1

32 ± 6

CL2 Percent Change Results
There were no differences in the percent decrements in total work (-10.52 ± 10.62% vs.
PL -21.3 ± 8.25%; Figure 13) and average power (-14.39 ± 4.54% vs. -21.98 ± 8.28;
Figure 14) between CR and PL after immobilization during the CL2 exercise bout.
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Figure 13. Percentage change in constant load bout 2 work (J) after immobilization
from creatine and placebo. Values are mean ± SE.

Figure 14. Percentage change in constant load bout 2 power (W) after immobilization
from creatine and placebo. Values are mean ± SE.
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Discussion
Consistent with our hypothesis and prior research (17), CR attenuated the reduction in
total work and average power during the first endurance bout. There could be several
reasons why CR supplementation slowed the loss in muscle endurance. Following
incremental exercise to exhaustion, CR supplementation could have increased or
maintained muscle creatine phosphate (CP) content (13). An increase in CP stores and/or
free CR could enhance the reversibility of the CK reaction during the first rest period
following the incremental protocol thus improving CP recovery kinetics (7, 12, 35).
However, no improvement in endurance occurred during the second endurance bout. This
may be due to the limited potential for a small muscle group like the forearms to store
sufficient CP to enhance performance on multiple exercise bouts. Perhaps the CP
depletion was severe enough to limit the CP recovery kinetics between the first and
second endurance bouts or there was insufficient time to recover the CP stores. Fatigue
could also have been influenced by the increased involvement of other energy pathways
(e.g. glycolysis) during the endurance bouts. Finally, neural impairments such as
decreased central activation and increases in long-interval intracortical inhibition may
have played a more prominent role in fatigue during the final endurance bout (8). It is
well established that neuromuscular changes occur during immobilization that contribute
to post-immobilization decrements in muscle strength and endurance (21).

Deficits in muscle strength and endurance following immobilization cannot entirely be
accounted for by decreases in muscle CSA and neural alterations. Metabolic factors,
including changes in inorganic phosphate (Pi), have been shown to contribute to altered
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muscle contractile function (9). Pathare et al. (2005) studied the effects of 7 weeks of
immobilization of the ankle joint on skeletal muscle using 31P MRS and muscle biopsy.
Following immobilization, there was a significant decrease in plantar flexor torque and a
significant increase in the Pi concentration. Single fiber measurements demonstrated an
inverse relationship between Pi concentration and relative force production. The
alterations in resting Pi concentration may contribute to strength deficits during
immobilization independent of decreases in CSA and neuromuscular impairments (26).
These results suggest that CR supplementation may be able to play a role in maintaining
muscle function during immobilization by maintaining a lower Pi/PCr ratio and thus
mitigating the decrease in muscle force production.

No difference between groups in work and power decrement during the incremental
protocol post-immobilization was a surprising result of this study. Previous research has
shown a 29.3% drop in isometric wrist flexion strength following 9 d of wrist/forearm
immobilization and suspension (25). Research by Clark et al. (2010) reported a 43.2%
decrease in maximal voluntary isometric contraction for the wrist flexors following 3
weeks of wrist/hand immobilization (8). In this study, wearing a cast for one week
modestly decreased the total work and average power that could be produced during
dynamic forearm flexion. The inconsistent results between the present study and the
previous studies could be due to the type of muscle contraction. The previous studies
measured isometric wrist strength instead of the dynamic wrist flexion measured in the
present study (8, 25). Changes in dynamic muscle endurance may be affected at a
different rate than isometric muscle actions. Another possible explanation could be the
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length of the immobilization period. It is well established that muscle dysfunction
increases as a function of the length of the immobilization period (11, 33). One week may
be too short a time period to demonstrate the magnitude of performance decrements in
the wrist flexors as reported for larger muscle groups. Perhaps two or three weeks of
immobilization would have resulted in a larger decrease in work and power performance,
and allowing the possibility that CR supplementation may offset the decrements we
found during the incremental protocol and the CL2 exercise bout.

Improvement in endurance in the first CL1 endurance bout agrees with Johnston et al.
(17). However, the improvement did not continue into the second CL2 endurance bout.
One possible explanation for the initially positive endurance effects of Cr could be
related to an effect on the phosphocreatine energy system. This suggestion could be
resolved using 31 P-MRS to quantify the CP, CR, inorganic phosphate (Pi), and pH of the
muscle during exercise and the recovery periods (23, 24, 29). One of the main benefits of
CR supplementation is its ability to increase CP stores (12), which can be measured with
31

P-MRS (28, 36). Changes in CP stores, the CP/Pi ratio, as well as CP recovery kinetics

following the incremental bout and between CL1 and CL2 may help explain the
differences in exercise endurance (2, 9, 19, 30).

This study grouped males and females together based on prior research demonstrating
similar decreases in isometric and isokinetic wrist flexion strength in male and female
subjects (25). Although peak load during the incremental protocol along with total work
and average power were higher in male subjects, females responded with similar relative
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changes in strength and endurance during the immobilization period. In the present study,
there were no obvious sex differences in the responses of the CR and PL groups.

This study was unique in that it was the first to identify work and endurance decrements
during maximal and subsequent constant load dynamic wrist flexion exercise following
one week of immobilization. Cr supplementation during 7 days of immobilization
minimized the loss of endurance during the first constant load exercise bout. This could
have important applications to patients recovering from limb immobilization, the elderly
who experience muscle mass, strength, and endurance loss, and astronauts living in
microgravity. The muscle mass and joint function measured (18), the type of muscle
contraction measured (isometric versus dynamic) (31), and the exercise test protocol (16),
may all affect the effectiveness of CR to support muscle performance (22). Future
research should measure muscle high-energy phosphate compounds (e.g. CP) and acidity
to explain the underlying mechanisms contributing to fatigue, along with recovery
kinetics during subsequent bouts of exercise. A further understanding of the mechanisms
behind this phenomenon (ability of CR to enhance endurance after immobilization) may
allow additional improvement in our ability to prescribe ergogenic agents to enhance
recovery of immobilized individuals.
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CHAPTER 4
SUMMARY, CONCLUSION, AND RECOMMENDATIONS

Summary
The review manuscript titled “Exploring the Potential of Creatine to Maintain
Muscle Function During Immobilization” made a unique contribution to Exercise
Physiology by providing insight regarding the effectiveness of Cr supplementation on
muscle performance following short duration immobilization. The biochemistry of Cr,
the effectiveness of Cr on short intense exercise and long-duration exercise, mechanisms
behind the ergogenic benefits, and safety were addressed. In addition, the review
manuscript discussed limited data demonstrating the ergogenic nature of Cr
supplementation during immobilization. The manuscript also discussed the muscle
metabolic effects of Cr and immobilization on muscle size and performance. Further, the
manuscript addressed how 31P-MRS research during exercise and recovery may be able
to determine the effect of Cr supplementation has on muscle metabolic function.
The research manuscript titled “Effect of Creatine Supplementation on Wrist
Flexion Work and Power after Immobilization” contributed to Exercise Physiology by
providing evidence that short duration wrist immobilization results in significant
decreases in dynamic forearm ergometry exercise performance. Moreover, Cr
supplementation during the week of immobilization mitigated the drop in exercise
endurance during the first constant load exercise bout following a brief rest following
incremental exercise to fatigue. This finding is consistent with other research that has
demonstrated Cr to be effective at slowing the loss of muscle performance during
immobilization. This study is unique in that it was the first to measure dynamic wrist
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flexion exercise performance following immobilization. In addition, this study measured
forearm ergometry during an incremental protocol to fatigue as well as subsequent
constant load muscle endurance.

Conclusions
The significant findings presented in the research manuscript were; a) 7 days of
wrist immobilization significantly decreased exercise endurance, b) this decrement was
slowed with creatine supplementation for an initial constant load exercise bout, c) there
was no significant difference between the creatine or placebo groups for the incremental
protocol, and, d) although there was an initial improvement in endurance during the first
endurance exercise bout, there was no significant difference between creatine or placebo
for the second constant load exercise bout. These results suggest that creatine ingestion
during conditions of muscle wasting may help maintain at least short-term muscle
endurance and power, which could be helpful during the initial phases of rehabilitation.

Recommendations
In hindsight, there are a few things that could have been done differently to
improve upon this research. First, using an electronic ergometer with a radial encoder to
quantify work and power for each wrist flexion repetition would have improved the
accuracy of the ergometry data. Second, increasing the duration of the constant load
exercise bouts to fatigue would have better reflected muscle endurance, as some subjects
completed all of the repetitions prior to complete fatigue. Finally, due to the large
deviations in muscle work and power during the exercise tests, increasing the number of
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subjects in each group would have enhanced the statistical power and improve sensitivity
of detecting significant differences between groups.
It is recommended that future research studies; a) investigate the metabolic effects
of immobilization and the role of high energy phosphate compounds during exercise and
recovery, b) increase the duration of the immobilization period when examining muscle
performance decrements at the wrist, c) increase the number of intermittent constant load
exercise bouts when studying the effectiveness of Cr supplementation on muscle
performance, d) investigate the effectiveness of Cr supplementation on muscle
performance during longer duration (> 2 weeks) immobilization protocols, e) determine if
Cr is an effective countermeasure during other muscle disuse scenarios (e.g. bed rest), f)
investigate the effectiveness of supplementing Cr before the immobilization period.
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APPENDIX A

The University of New Mexico Health Sciences Center Consent to
Participate in Research
Version Date: 2/22/2011
Effect of Creatine Supplementation on High Energy Phosphate
Kinetics after Immobilization
Introduction
You are being asked to participate in a research study that is being done by Suzanne
Schneider Ph.D., who is the Principal Investigator and Jeremy C. Fransen, a Ph.D.
Candidate, from the Department of Health Exercise and Sport Sciences. This research
is studying the effectiveness of creatine supplementation on muscle energy metabolism
following wrist immobilization.
You are being asked to participate in this study because of your status as someone that
engages in a regular exercise training program of at least 2 times per week of resistance
exercise for more than 30 minutes per session. Twenty-four people will take part in
this study at the University of New Mexico.
This form will explain the research study, and will also explain the possible risks
as well as the possible benefits to you. We encourage you to talk with your family
and friends before you decide to take part in this research study. If you have any
questions, please ask one of the study investigators.

What will happen if I decide to participate?
If you agree to participate, the following things will happen:

Procedures
If you decide to participate, you will be asked to report to New Mexico Resonance
located at 2301 Yale Blvd. SE, Albuquerque, NM on 3 separate occasions for testing
that will take approximately 2 hours each. Prior to the first testing session, you will be
asked to complete a health history questionnaire. Female participants will be asked to
take a pregnancy test. Pregnant women will be excluded from the study.
1) For the first testing session, you will perform a familiarization exercise and recovery
test, which consists of wrist/forearm flexion exercise to fatigue with your nondominant arm inside a MRI/MRS magnet to measure muscle metabolism. The
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incremental protocol will be accomplished by adding 0.5 to 1.0 kg weights attached to
a wall pulley exercise device located inside the bore of the magnet. Following exercise
to fatigue, your forearm will remain inside the magnet for 5 minutes to obtain muscle
metabolism recovery data. You will then perform 2 minutes of continuous exercise
followed by 20 minutes of recovery data. Your arm will remain inside the magnet
during the entire exercise and recovery bouts.
2) The second session will begin with a measure for muscle volume. Your nondominant hand/forearm will be submerged to the elbow in a tank of water to measure
water displacement, and thus limb size. You will then perform the exercise session,
where you will perform incremental forearm flexion to fatigue, followed by 5 minutes
of recovery. You will then perform 2 minutes of forearm flexion exercise with a load
equal to the maximal load achieved during the incremental test. You will then rest 5
minutes. After the rest, you will once again perform 2 minutes of forearm flexion
exercise with the same load as the last 2 min exercise bout. You will then rest for 30
minutes to obtain complete recovery data. Your forearm will remain inside the magnet
during the entire exercise testing and recovery sequence.
Following the second testing session with the magnet, your non-dominant arm will be
placed in a plaster cast covering the forearm below the elbow to the mid palm of the
hand. You will then be instructed to consume 5 grams of a powdered supplement,
either creatine or placebo, mixed with water twice on that day with meals, for a total of
10 grams. The cast will remain on for the next 7 days during which time you will be
instructed to consume 5 grams of creatine or placebo four times per day mixed with
water during meals for a total of 20 grams per day.
3) The third testing session will begin on day 8, following the 7 days of casting. You
will be instructed to ingest 5 grams of supplement at breakfast the morning before
testing. Once you arrive at NMR, the forearm/hand cast will be removed. Your
forearm will then be placed into a tank of water to measure limb size. Next, the
exercise testing will be conducted in the magnet. The protocol will be identical to the
pre-casting sequence as described above.

How long will I be in this study?
Participation in this study will take a total of 6 hours over a period of 3 sessions of 2
hours each. Participation will also include the non-dominant arm being in a
wrist/forearm cast for 7 days.

What are the risks or side effects of being in this study?
•

Possible side effects of maximal forearm exercise may include brief feelings of
muscle fatigue and discomfort while performing wrist flexion exercise. In addition,
you may have localized discomfort with the forearm and hand while it rests inside
the magnet during the rest periods. Because the exercise bouts consist of muscle
contractions, there is a risk of developing delayed muscle soreness in the forearm
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muscles. The forearm muscle may lose strength and size during the week of cast
immobilization. However, these changes will most likely small and only
measureable by using the sensitive testing methodology of the magnet. Muscle
recovery following short-term cast immobilization is rapid. Finally, there is a
possibility of pain or discomfort if the cast becomes tight as a result of water
weight gain associated with creatine. All personnel conducting the test have
previous exercise testing experience and are aware of the signs and symptoms that
are associated with possible adverse reactions during muscle exercise.
•

An MRS machine acts like a large magnet, so it could move iron-containing objects
in the room during your examination. Precautions have been taken to prevent any
such event from happening and injuring you. You cannot have an MRS if you have
a pacemaker or any metal in your body, such as an aneurysm clip, ear implant,
nerve stimulator or any other metal permanent metal implants. It is unknown what,
if any, the risks of a MRS are to a fetus, therefore women who are pregnant should
not participate in this study.

•

There is a risk of gastrointestinal discomfort; specifically, upset stomach, vomiting
and diarrhea related to creatine.
You will be ingesting a supplement that may cause a 2 to 4 lbs gain in body weight.
This gain in body weight is associated with an increase in body water. The body
weight gain is temporary and you should lose this weight within 2 weeks following
the research study. However, there is a possibility that the water gain may cause
the cast to become tight. If the tightness causes severe pain or numbness in the
hand/forearm, please contact Jeremy Fransen at 702-917-3724 immediately to have
the cast removed.

•

There is a risk that the limited range of motion may compromise your ability to
drive an automobile. There is a possibility you may not be able to drive during the
7 days in a cast. If you do drive, there is a possibility that you may not be covered
by your insurance company. Please refer to your current automobile insurance
policy for specific information.

•

There are risks of stress, emotional distress, inconvenience and possible loss of
privacy and confidentiality associated with participating in a research study.

For more information about risks and side effects, ask your study doctor.

What are the benefits to being in this study?
You may receive no benefits from this study. However, results from the incremental
exercise test will give you information concerning your forearm muscle power and
metabolism during exercise and recovery. Furthermore, information gained from using
sensitive, state-of- the-art equipment to measure muscle metabolism and function
following short-term immobilization will enhance the scientific knowledge concerning

81
muscle disuse. Finally, if the creatine supplement intervention slows changes in muscle
during immobilization, this could result in a new therapy that would have wide- range
application to patients that are immobilized following injury.

What other choices do I have if I do not want to be in this study?
The only alternative is to not participate in this study.

How will my information be kept confidential?
We will take measures to protect your privacy and the security of all your personal
information, but we cannot guarantee confidentiality of all study data.
The University of New Mexico Health Sciences Center Human Research Review
Committee (HRRC) that oversees human subject research, along with the PI and
co-investigator, will be permitted to access your records. There may be times
when we are required by law to share your information. However, your name will
not be used in any published reports about this study. A copy of this consent form will
be kept in your medical record.

What are the costs of taking part in this study?
You will not be charged for any of the study’s procedures.

What will happen if I am injured or become sick because I took part
in this study?
If you are injured or become sick as a result of this study, UNMHSC will provide you
with emergency treatment, at your cost. No commitment is made by the University
of New Mexico Health Sciences Center (UNMHSC) to provide free medical care or
money for injuries to participants in this study.
In the event that you have an injury or illness that is caused by your participation in
this study, reimbursement for all related costs of care will be sought from your
insurer, managed care plan, or other benefits program. If you do not have insurance,
you may be responsible for these costs. You will also be responsible for any associated
co-payments or deductibles required by your insurance.
It is important for you to tell your study doctor immediately if you have been injured
or become sick because of taking part in this study. If you have any questions about
these issues, or believe that you have been treated carelessly in the study, please
contact the Human Research Review Committee (HRRC) at the University of New
Mexico Health Sciences Center, Albuquerque, New Mexico 87131, (505) 272-1129 for
more information.

Will I be paid for taking part in this study?
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Yes, you will be compensated $100.00 for your participation in this study.
Compensation will be pro- rated based on time of participation. You will be
compensated for each of the three sessions as follows: $20 for the first session, $40 for
the second and $40 for the final session.

How will I know if you learn something new that may change my mind
about participating?
You will be informed of any significant new findings that become available during the
course of the study, such as changes in the risks or benefits resulting from participating
in the research or new alternatives to participation that might change your mind about
participating.

Can I stop being in the study once I begin?
Your participation in this study is completely voluntary. You have the right to choose
not to participate or to withdraw your participation at any point in this study without
affecting your future health care or other services to which you are entitled.

Whom can I call with questions or complaints about this study?
If you have any questions, concerns or complaints at any time about the research study,
Suzanne Schneider, Ph.D., or her associates will be glad to answer them at (505) 2772658, Monday through Friday 8:00am – 5:00pm. If you need to contact someone after
business hours or on weekends, please call at 272-4751 (pager), and ask for Dr.
Akshay Sood (Medical Director of the EPL). If you would like to speak with someone
other than the research team, you may call the UNMHSC HRRC at (505)
272-1129.

Whom can I call with questions about my rights as a research subject?
If you have questions regarding your rights as a research subject, you may call the
UNMHSC HRRC at (505) 272-1129. The HRRC is a group of people from UNM and
the community who provide independent oversight of safety and ethical issues related
to research involving human subjects. For more information, you may also access the
HRRC website at http://hsc.unm.edu/som/research/hrrc/.
CONSENT
You are making a decision whether to participate in this study. Your signature below
indicates that you read the information provided. By signing this consent form, you are
not waiving any of your legal rights as a research subject.
I have had an opportunity to ask questions and all questions have been answered to my
satisfaction. By signing this consent form, I agree to participate in this study. A copy
of this consent form will be provided to you.
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Name of Subject (print)

Signature of Subject

Date

INVESTIGATOR SIGNATURE
I have explained the research to the subject and answered all of his/her questions. I
believe that he/she understands the information described in this consent form and
freely consents to participate.

Name of Investigator/ Research Team Member (type or print)

(Signature of Investigator/ Research Team Member)

Date
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APPENDIX B
UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER HIPAA1
AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION
FOR RESEARCH PURPOSES
Title of Study: Effect of Creatine Supplementation on High Energy Phosphate Kinetics after
Immobilization

Principal Investigator:
UNMHSC Department:
Mailing Address:
Co-Investigators:

Suzanne Schneider
Health, Exercise & Sport Sciences
sschneid@unm.edu
Jeremy C. Fransen, Micah Zuhl, Nicole Vargas, Robert
Robergs

Sponsor: N/A
1. What is the purpose of this form? You have been asked to take part in a research study. The
consent form for this study describes your participation, and that information still applies. This
extra form is required by the federal Health Insurance Portability and Accountability Act (HIPAA).
The purpose of this form is to get your permission (authorization) to use health information about
you that is created by or used in connection with this research.
2. What if I don’t want my personal health information (PHI) to be used in this research study?
You do not have to give this permission. Your decision not to sign this form will not change your
ability to get health care outside of this research study. However, if you do not sign, then you will
not be allowed to participate in the study.
3. What PHI am I allowing to be used for this research? The information that may be used -------includes: Health history and current health status, height, weight, age, gender, forearm muscle
power, forearm muscle volume, and muscle metabolites (ATP, Pi, PCr, pH) as measured by
magnetic resonance spectroscopy (31P MRS) during exercise and recovery from exercise. Muscle
strength, size, and metabolism measurements before and after 7 days of forearm/wrist casting will
be compared to a supplement intervention versus placebo.
4. Where will researchers go to find my PHI? We may ask to see your personal information in
records at hospitals, clinics or doctor’s offices where you may have received care in the past,
including but not limited to facilities in the UNM health care system.
5. Who will be allowed to use my information for this research and why? The researchers named
AccIt may be used to check on your progress during the study, or analyze it along with information
from other study participants. Sometimes research information is shared with collaborators or other
institutions. Your records may also be reviewed by representatives of the research sponsor or
funding agency, the Food and Drug Administration (FDA) to check for quality, safety or
effectiveness, or the Human Research Review Committee (HRRC) for the purposes of oversight
and subject safety and compliance with human research regulations.

___________________________
1

HIPAA is the Health Insurance Portability and Accountability Act of 1996, a federal law
related to privacy of health information.
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6. Will my information be used in any other way? Your information used under this permission
may be subject to re-disclosure outside of the research study and be no longer protected under
certain circumstances such as required reporting of abuse or neglect, required reporting for law
enforcement purposes, and for health oversight activities and public health purposes.
7. What if I change my mind after I give this permission? You can change your mind and
withdraw this permission at any time by sending a written notice to the Principal Investigator at the
mailing address listed at the top of this form to inform the researcher of your decision. If you
withdraw this permission, the researcher may only use and share your information that has already
been collected for this study. No additional health information about you will be collected by or
given to the researcher for the purposes of this study.
8. What are the privacy protections for my PHI used in this research study? HIPAA regulations
apply to personal health information in the records of health care providers and other groups that
share such information. There are some differences in how these regulations apply to research, as
opposed to regular health care. One difference is that you may not be able to look at your own
records that relate to this research study. These records may include your medical record, which
you may not be able to look at until the study
is over. The HIPAA privacy protections may no longer apply once your PHI has been shared with
others who may be involved in this research.
9. How long does this permission allow my PHI to be used? If you decide to be in this research
study, your permission to access and use your health information in this study may not expire,
unless you revoke or cancel it. Otherwise, we will use your information as long as it is needed for
the duration of the study.

I am the research participant or the personal representative authorized to act on behalf of the
participant. By signing this form, I am giving permission for my personal health information to be
used in research as described above. I will be given a copy of this authorization form after I have
signed it.

Name of Research Subject

Name of Person Obtaining Authorization

Signature of Subject

Date

Signature

Date
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APPENDIX C
HEALTH HISTORY QUESTIONNAIRE
Subject #________

Date___/___/___

Date of Birth ___/___/___

Phone (H) _________ (Cell) ___________

Age____ Gender____ Ethnicity______

Address (home) ______________________________________________zip_________
♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

MEDICAL HISTORY
Self-reported: Height______

Weight______

Physical injuries:___________________

____________________________________

Limitations______________________________________________________________
Have you ever had any of the following cardiovascular problems? Please check all that
apply.
Heart attack/Myocardial Infarction____
Chest pain or pressure
____
Arrhythmias/Palpitations
____
Valve problems
____
Congestive heart failure
____

Heart surgery
Swollen ankles
Heart murmur
Dizziness

____
____
____
____

Have you ever had any of the following? Please check all that apply.
Hepatitis/HIV
Rheumatic fever
Kidney/liver disease
Diabetes (specify type)
Emphysema
Depression
Total cholesterol >200 mg/dl
LDL cholesterol >135 mg/dl
Neuromuscular disease

_____
_____
_____
_____
_____
_____
_____
_____
_____

Cancer (specify type)
High blood pressure
Obesity
Asthma
Stroke
Thyroid problems
HDL cholesterol <35 mg/dl
Trigylcerides >150 mg/dl

____
____
____
____
____
____
____
____

(e.g. myasthenia gravis, rheumatoid arthritis, multiple sclerosis, muscular dystrophy, etc.)

If yes, describe ______________
Do immediate blood relatives (biological parents & siblings only) have any of the
conditions listed above? If yes, list the problem, and family member age at diagnosis.
________________________________________________________________________
Do you have any metal implants or metallic objects in your body?
Do you have any tattoos? Y N

Y N
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Do you currently have any condition not listed that may influence test results? Y

N

Details__________________________________________________________________
Indicate level of your overall health. Excellent ____ Good ____ Fair ____ Poor_____
Are you taking any medications, vitamins or dietary supplements now?
Y N
If yes, what are they?_____________________________________________________
Have you ever taken creatine monohydrate?

Y N

If yes, when was the last time you took creatine? ___________________
Are you allergic to latex?

Y

N

Have you ever experienced any adverse effects during or after exercise (fainting,
vomiting, shock, palpitations, hyperventilation)? Y N If yes, elaborate._____________

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

LIFESTYLE FACTORS
How often do you drink the following?
Caffeinated coffee, tea, or soda _____oz/day
What do you do for physical activity/exercise now? ____________________________
How often do you exercise? ____________

How long per session?________

Do you regularly perform resistance exercise or weight training exercise?

Y N

If yes, how many days per week do you train with weights? ______________
Estimate your exercise intensity level or exercise heart rate.________________
Indicate your current level of emotional stress. High____

Moderate ____

Low____

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

WOMEN ONLY
Are you pregnant or could you be pregnant?

Y N

Please check the response that most closely describes your menstrual status:
_____ Post-menopausal (surgical or absence of normal menstrual periods for 12 months)
_____ Eumenorrheic – Normal menstrual periods (~every 28 days)
_____ Amenorrheic – Absence of normal menstrual periods for at least 3 months
_____ Oligomenorrheic – Irregular menstrual periods with occasional missed cycles.
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APPENDIX D
Table 5. Pre- Immobilization PL
Subject
Cr/PL
Gender
1
PL
F
5
PL
F
7
PL
F
11
PL
F
16
PL
F
19
PL
F
22
PL
F
3
PL
M
6
PL
M
8
PL
M
14
PL
M
26
PL
M
Mean
Std Dev
n

Table 6. Post- Immobilization PL
Subject
Cr/PL
Gender
1
PL
F
5
PL
F
7
PL
F
11
PL
F
16
PL
F
19
PL
F
22
PL
F
3
PL
M
6
PL
M
8
PL
M
14
PL
M
26
PL
M
Mean
Std Dev
n

Incr J
321.78
248.23
183.87
248.23
248.23
404.52
321.78
643.56
809.05
496.46
496.46
496.46

Incr W
4.29
3.31
2.45
3.31
3.31
5.39
4.29
8.58
10.79
6.62
6.62
6.62

CL1 J
141.22
123.56
105.91
123.56
123.56
158.87
141.22
282.43
317.74
247.13
247.13
247.13

CL1 W
0.98
0.86
0.74
0.86
0.86
1.10
0.98
1.96
2.21
1.72
1.72
1.72

CL2 J
138.27
123.56
105.91
123.56
123.56
158.87
138.27
282.43
317.74
247.13
247.13
247.13

CL2W
0.98
0.86
0.74
0.86
0.86
1.10
0.98
1.96
2.21
1.72
1.72
1.72

409.89
186.22
12

5.47
2.48
12

188.29
74.26
12

1.31
0.52
12

187.80
74.60
12

1.31
0.52
12

Incr J
321.78
188.63
183.87
248.23
248.23
404.52
321.78
533.24
809.05
496.46
496.46
496.46

Incr W
4.29
2.52
2.45
3.31
3.31
5.39
4.29
7.11
10.79
6.62
6.62
6.62

CL1 J
141.22
58.64
105.91
123.56
44.62
39.72
125.53
247.13
308.91
15.69
185.35
219.67

CL1 W
0.98
0.41
0.74
0.86
0.31
0.28
0.87
1.72
2.15
0.11
1.29
1.53

CL2 J
129.45
102.97
105.91
123.56
0.00
97.09
133.37
219.67
300.08
141.22
233.40
212.80

CL2 W
0.90
0.72
0.74
0.86
0.00
0.67
0.93
1.53
2.08
0.91
1.62
1.48

395.73
181.53
12

5.28
2.42
12

134.66
90.92
12

0.94
0.63
12

149.96
79.32
12

1.04
0.55
12
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Table 7. Pre-Immobilization CR
Subject
Cr/PL
Gender
2
Cr
F
12
Cr
F
17
Cr
F
21
Cr
F
4
Cr
M
10
Cr
M
13
Cr
M
15
Cr
M
18
Cr
M
20
Cr
M
23
Cr
M
24
Cr
M
25
Cr
M
Mean
Std Dev
n

Table 8. Post-Immobilization CR
Subject
Cr/PL
Gender
2
Cr
F
12
Cr
F
17
Cr
F
21
Cr
F
4
Cr
M
10
Cr
M
13
Cr
M
15
Cr
M
18
Cr
M
20
Cr
M
23
Cr
M
24
Cr
M
25
Cr
M
Mean
Std Dev
n

Incr J
321.78
183.87
404.52
248.23
643.56
321.78
496.46
643.56
643.56
643.56
496.46
367.75
643.56

Incr W
4.29
2.45
5.39
3.31
8.58
4.29
6.62
8.58
8.58
8.58
6.62
4.90
8.58

CL1 J
141.22
105.91
158.87
123.56
282.43
141.22
247.13
282.43
282.43
282.43
247.13
211.82
282.43

CL1 W
0.98
0.74
1.10
0.86
1.96
0.98
1.72
1.96
1.96
1.96
1.72
1.47
1.96

CL2 J
138.27
105.91
158.87
123.56
282.43
138.27
247.13
282.43
282.43
282.43
247.13
211.82
282.43

CL2 W
0.98
0.74
1.10
0.86
1.96
0.98
1.72
1.96
1.96
1.96
1.72
1.47
1.96

466.05
168.71
13

6.21
2.25
13

214.54
70.18
13

1.49
0.49
13

214.09
70.70
13

1.49
0.49
13

Incr J
321.78
138.68
404.52
248.23
619.04
321.78
496.46
643.56
643.56
643.56
496.46
367.75
608.32

Incr W
4.29
1.85
5.39
3.31
8.25
4.29
6.62
8.58
8.58
8.58
6.62
4.90
8.11

CL1 J
141.22
94.14
150.04
123.56
258.90
137.29
199.07
251.05
251.05
251.05
247.13
188.29
266.74

CL1 W
0.98
0.65
1.04
0.86
1.79
0.95
1.38
1.74
1.74
1.74
1.16
1.31
1.85

CL2 J
138.27
88.26
141.22
123.56
243.20
137.29
205.94
258.90
282.43
258.90
247.13
211.82
109.83

CL2 W
0.91
0.61
0.98
0.86
1.69
0.95
1.43
1.78
1.91
1.78
1.16
1.41
0.76

457.98
170.51
13

6.11
2.27
13

196.89
61.17
13

1.32
0.41
13

188.21
66.99
13

1.25
0.44
13
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Table 9. Pre to Post % Change for PL
Subject
Cr/PL
Gender
Incr J
1
5
7
11
16
19
22
3
6
8
14
26

PL
PL
PL
PL
PL
PL
PL
PL
PL
PL
PL
PL

F
F
F
F
F
F
F
M
M
M
M
M

Mean
Std Dev
n

Incr W

CL1 J

CL1 W

CL2 J

CL2 W

0
-24.01
0
0
0
0
0
-17.14
0
0
0
0

0.00
-24.01
0.00
0.00
0.00
0.00
0.00
-17.14
0.00
0.00
0.00
0.00

0.00
-52.54
0.00
0.00
-63.89
-75.00
-11.11
-12.50
-2.78
-93.65
-25.00
-11.11

0.00
-52.56
0.68
0.00
-63.87
-74.98
-11.02
-12.48
-2.81
-93.65
-25.01
-11.14

-6.38
-16.67
0.00
0.00
-100.00
-38.89
-3.55
-22.22
-5.56
-42.86
-5.56
-13.89

-8.27
-16.67
-0.07
0.00
-100.00
-38.89
-5.51
-22.25
-5.57
-47.15
-5.55
-13.88

-3.17
7.85
12

-3.43
8.14
12

-28.96
33.31
12

-28.90
33.36
12

-21.30
28.58
12

-21.98
28.70
12

Incr W

CL1 J

CL1 W

CL2 J

CL2 W

0
-24.58
0
0
-3.81
0
0
0
0
0
0
0
-5.48

0.00
-24.58
0.00
0.00
-3.81
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-5.48

0.00
-11.11
-5.56
0.00
-8.33
-2.78
-19.44
-11.11
-11.11
-11.11
0.00
-11.11
-5.56

0.00
-11.08
-5.53
0.00
-8.94
-2.76
-19.47
-11.13
-11.13
-11.13
-32.29
-11.09
-5.58

0.00
-16.67
-11.11
0.00
-13.89
-0.71
-16.67
-8.33
0.00
-8.33
0.00
0.00
-61.11

-7.52
-16.66
-11.06
0.00
-13.89
-2.82
-16.68
-9.25
-2.42
-9.25
-32.29
-4.09
-61.10

-2.61
6.83
13

-2.61
6.83
13

-7.48
5.83
13

-10.01
8.59
13

-10.52
16.60
13

-14.39
16.37
13

Table 10. Pre to Post % Change for CR
Subject
Cr/PL
Gender
Incr J
2
12
17
21
4
10
13
15
18
20
23
24
25
Mean
Std Dev
n

Cr
Cr
Cr
Cr
Cr
Cr
Cr
Cr
Cr
Cr
Cr
Cr
Cr

F
F
F
F
M
M
M
M
M
M
M
M
M
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APPENDIX E

Supplement Protocol:
Day 1: Get casted. Take 2 servings (1a, 1b) spaced out that day (i.e. lunch, dinner)
Day2: Take 4 servings (2a, 2b, 2c, 2d) spaced out evenly (i.e. breakfast, lunch, dinner,
nighttime snack)
Day 3 – Day 7: Same as day 2 (3a, 3b, 3c, 3d; 4a, 4b, 4c, 4d; etc.)
Day 8: Take one serving (8a) with breakfast. Cast comes off. Do Post-test at NMR

Mixing procedure:
1. Place mixing jug on a plate or large bowl to catch any powder that may fall out of the
container.
2. Pour powder contents into container being careful not to spill.
3. Take empty baggy and put that back into the large plastic bag.
4. Add warm (room temp) water to the 300 ml line on side of container.
5. Mix thoroughly making sure all powder is dissolved.
6. Drink
Notes:
-Take the supplement with meals. This helps absorption.
-Try to drink more water throughout the day.
-Please use at least room temperature or slightly warm water. This helps the powder
dissolve and improves absorption.
-KEEP ALL THE BAGGIES!!! This is important, as I will count up all the baggies
when you return them in the big plastic bag.
-If you forget a dose, just make sure to get it in at the next meal. You want to make sure
you get all the required doses on that day.
-Do not take supplement with caffeine. If you must, you can have a coffee or soda, just
do it between meals when not consuming the supplement.
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APPENDIX F

Trial_______
Cycle

Subject # _____
Load (kg)

Reps

1

2
3

4

5

6

7

8

9

SS Load______

SS#1 reps ________

SS#2 reps_______
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APPENDIX G

UNM Participant Form:
This form is used to set up all participants as venders in the UNM System for payment
purposes. After the participant has been processed the participant will be assigned banner
ID # and this form will be destroyed. Thank you for participating in this study.

Project Name: Effect of Creatine Supplementation on High Energy Phosphate
Kinetics after Immobilization
Participant Legal Name:
________________________________________________________

Address:
________________________________________________________

________________________________________________________

Phone #:
(______)_________________________________________________

Social Security number:
________________________________________________________________

Amount to be Paid:
$___100.00________________________________________________

